EUVIMEDEUVIMED entdecken
Crossref

Induction of UBQLN1 ‐mediated PGC1α stability by isoliensinine overcame hypoxia‐induced resistance in liver cancer cells

Xuefen Xu iD, Wei Li, Ya Zhou, Meihui Wang, Shufan Ji, Siwei Xia, Yang Li, Xiaohan Guo, Sheng Huan, Feixia Wang, Feng Zhang, Haibo Cheng und 2 weitere

BioFactors · 2025

DOI: 10.1002/biof.70008 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BioFactors, 2025. Verfasst von Xuefen Xu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, School of Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, People's Republic of China. Hauptthemen laut MEDLINE: Liver Neoplasms, Autophagy-Related Proteins, Drug Resistance, Neoplasm, Adaptor Proteins, Signal Transducing. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Nanjing University of Chinese Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hypoxia is a key reason for the failure of liver cancer therapy. Emerging evidences indicated that ROS played a crucial role in the sorafenib therapy, and overcoming the reduction in intracellular ROS levels was the first requirement for therapy resistance. Ubiquilin1 (UBQLN1) acted as an oncogene or suppressor gene involved in the protein degradation and abnormal protein aggregation. In this study, we proposed a novel strategy to reverse the hypoxia‐induced resistance in liver cancer by isoliensinine (Iso), a significant bioactive compound derived from lotus seed. Based on preliminary screening, we found a significant elevation of UBQLN1 in liver cancer tissues obtained from the TCGA databases and in liver cancer cells under hypoxic model, which contributed to hypoxia‐induced sorafenib resistance. Further data suggested that Iso significantly reversed the hypoxia‐induced sorafenib resistance through directly targeting UBQLN1 and inducing ROS production. Notably, the ROS elevation induced by Iso could trigger IRP2‐induced ferroptosis but remained below the threshold for mitochondrial damage in liver cancer cells. The related mechanism was that Iso reduced the binding between PGC1α and ubiquitin, promoting the stability of the PGC1α protein, which might accelerate mitochondrial energy metabolism. Taken together, our findings not only revealed that UBQLN1 played a critical role in ROS regulation, but also uncovered a previously unrecognized reversal mechanism of Iso in liver cancer, which promoted sensitization of sorafenib‐induced ferroptosis by inhibition of UBQLN1/PGC1α pathway under hypoxia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver NeoplasmsAutophagy-Related ProteinsDrug Resistance, NeoplasmAdaptor Proteins, Signal TransducingPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaCell Cycle ProteinsHumansReactive Oxygen SpeciesCell Line, TumorSorafenibGene Expression Regulation, NeoplasticProtein StabilityCell HypoxiaHep G2 Cells

Stichwörter der Autor:innen

PGC1αUBQLN1isoliensinineliver cancerresistance

Substanzen

Autophagy-Related ProteinsUBQLN1 protein, humanReactive Oxygen SpeciesAdaptor Proteins, Signal TransducingPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaSorafenibPPARGC1A protein, humanCell Cycle Proteins

Autor:innen und Institutionen

  • Department of Pharmacology, School of Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, People's Republic of China.
  • Jangsu Key Laboratory for Pharmacology and Safety Research of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, People's Republic of China.
  • Institute of Traditional Chinese Medicine (TCM)-Related Comorbid Depression, School of Chinese Medicine & School of Integrated Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, People's Repu…
  • Department of Anesthesiology, The Second Hospital of Nanjing, Nanjing, Jiangsu, People's Republic of China.
  • Jiangsu Collaborative Innovation Center of Traditional Chinese Medicine in Prevention and Treatment of Tumor, People's Republic of China.

ORCID-Profile: Xuefen Xu

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Nanjing University of Chinese Medicine

Zitieren

APA

Xu, X., Li, W., Zhou, Y., Wang, M., Ji, S., Xia, S., Li, Y., Guo, X., Huan, S., Wang, F., Zhang, F., Cheng, H., Yin, G., & Zheng, S. (2025). Induction of UBQLN1 ‐mediated PGC1α stability by isoliensinine overcame hypoxia‐induced resistance in liver cancer cells. BioFactors. https://doi.org/10.1002/biof.70008

Vancouver

Xu X, Li W, Zhou Y, Wang M, Ji S, Xia S, et al. Induction of UBQLN1 ‐mediated PGC1α stability by isoliensinine overcame hypoxia‐induced resistance in liver cancer cells. BioFactors. 2025. doi:10.1002/biof.70008

BibTeX
@article{Xu2025,
  author = {Xu, Xuefen and Li, Wei and Zhou, Ya and Wang, Meihui and Ji, Shufan and Xia, Siwei and Li, Yang and Guo, Xiaohan and Huan, Sheng and Wang, Feixia and Zhang, Feng and Cheng, Haibo and Yin, Guoping and Zheng, Shizhong},
  title = {Induction of UBQLN1 ‐mediated PGC1α stability by isoliensinine overcame hypoxia‐induced resistance in liver cancer cells},
  journal = {BioFactors},
  year = {2025},
  doi = {10.1002/biof.70008}
}
Kostenlos starten →